Global Antineoplastic Agents Market Insights and Forecast to 2028

New anti-tumor targets and corresponding new anti-tumor agents or means are: targeting cell signal transduction molecules, including protein tyrosine kinase inhibitors, farnesyltransferase (FTase) inhibitors, MAPK signaling pathway inhibitors, and cell cycle regulators.Targeting neovascularization: neovascularization inhibitors;To reduce the detachment, adhesion and basement membrane degradation of cancer cells: anti-metastasis drugs;Targeting telomerase: telomerase inhibitor;Drug resistance to tumor cells: drug resistance reversal agent;Promoting the mature differentiation of malignant cells: differentiation inducers;Specific killing of cancer cells :(antibody or toxin) directed therapy;Enhance the efficacy of radiotherapy and chemotherapy: tumor treatment sensitizers;Enhance or regulate collective immune function: biological response modulator;For oncogenes and tumor suppressor genes: gene therapy - introduction of wild-type tumor suppressor genes, suicide genes, anti-drug resistance genes and antisense oligonucleotides, tumor genetic engineering tumor bacteria.

Market Analysis and Insights: Global Antineoplastic Agents Market

The global Antineoplastic Agents market size is projected to reach US$ 4964.1 million by 2028, from US$ 4307.6 million in 2021, at a CAGR of 2.0% during 2022-2028.

Fully considering the economic change by this health crisis, by Treatment Means accounting for % of the Antineoplastic Agents global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period.

While Plant Medicine segment is altered to an % CAGR throughout this forecast period.

China Antineoplastic Agents market size is valued at US$ million in 2021, while the North America and Europe Antineoplastic Agents are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period.

As for the Europe Antineoplastic Agents landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Antineoplastic Agents market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Antineoplastic Agents market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Antineoplastic Agents market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Antineoplastic Agents market.

Global Antineoplastic Agents Scope and Market Size

Antineoplastic Agents market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Antineoplastic Agents market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

by Treatment Means

Chemotherapy

Targeted Therapy

Immunotherapy

Hormonal Therapy (Biologic Therapy)

Others

by Dosage Form

Injection

Tablets

Capsule

Suppository

Granules

Implant

其他

by Nature of the Drug

Pharmaceutical Chemicals

Biological Medicine

Natural Product

Plant Medicine

Hormone

Platinum Compounds

Metabolism Of Drug Resistance

Targeting Small Molecules

Drugs For Cancer

Antibiotic

Alkylating Agent

Chemoradiotherapy Protectant

BMS

MSD

Johnson & Johnson

Pfizer

AstraZeneca

Novartis

Sanofi

Celgene

Roche

Lilly

Bayer

Abraxis

Gilead

Wto-Day Order Pharmaceutical

Sinopharm

Shandong Lvye Pharmaceutical

CTTQ

Jiangsu Hengrui Pharmaceutical

Qilu Pharmaceutical

Baekdu Mountain Pharmaceutical

Baida Pharmaceutical

Jiangsu Haosen Pharmaceutical Group

Hainan Chang'an International Pharmaceutical

Zhejiang Kanglaite Pharmaceutical

Shandong New Era Pharmaceutical

Liaoning Novino Pharmaceutical

Maanshan Fengyuan Pharmaceutical

Meiluo Pharmaceutical

Shandong Luoxin Pharmaceutical Group

Zhejiang Yatai Pharmaceutical

Tesaro (GSK)

Eisai

Biogen Idec

Teva

AbbVie

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Antineoplastic Agents Market Size Growth Rate by Type, 2017 VS 2021 VS 2028

1.2.2 Chemotherapy

1.2.3 Targeted Therapy

1.2.4 Immunotherapy

1.2.5 Hormonal Therapy (Biologic Therapy)

1.2.6 Others

1.3 Market by Application

1.3.1 Global Antineoplastic Agents Market Size Growth Rate by Application, 2017 VS 2021 VS 2028

1.3.2 Plant Medicine

1.3.3 Hormone

1.3.4 Platinum Compounds

1.3.5 Metabolism Of Drug Resistance

1.3.6 Targeting Small Molecules

1.3.7 Drugs For Cancer

1.3.8 Antibiotic

1.3.9 Alkylating Agent

1.3.10 Chemoradiotherapy Protectant

1.3.11 Other

1.4 Study Objectives

1.5 Years Considered

2.1 Global Antineoplastic Agents Market Perspective (2017-2028)

2.2 Antineoplastic Agents Growth Trends by Region

2.2.1 Antineoplastic Agents Market Size by Region: 2017 VS 2021 VS 2028

2.2.2 Antineoplastic Agents Historic Market Size by Region (2017-2022)

2.2.3 Antineoplastic Agents Forecasted Market Size by Region (2023-2028)

2.3 Antineoplastic Agents Market Dynamics

2.3.1 Antineoplastic Agents Industry Trends

2.3.2 Antineoplastic Agents Market Drivers

2.3.3 Antineoplastic Agents Market Challenges

2.3.4 Antineoplastic Agents Market Restraints

3.1 Global Top Antineoplastic Agents Players by Revenue

3.1.1 Global Top Antineoplastic Agents Players by Revenue (2017-2022)

3.1.2 Global Antineoplastic Agents Revenue Market Share by Players (2017-2022)

3.2 Global Antineoplastic Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Antineoplastic Agents Revenue

3.4 Global Antineoplastic Agents Market Concentration Ratio

3.4.1 Global Antineoplastic Agents Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Antineoplastic Agents Revenue in 2021

3.5 Antineoplastic Agents Key Players Head office and Area Served

3.6 Key Players Antineoplastic Agents Product Solution and Service

3.7 Date of Enter into Antineoplastic Agents Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Antineoplastic Agents Historic Market Size by Type (2017-2022)

4.2 Global Antineoplastic Agents Forecasted Market Size by Type (2023-2028)

5.1 Global Antineoplastic Agents Historic Market Size by Application (2017-2022)

5.2 Global Antineoplastic Agents Forecasted Market Size by Application (2023-2028)

6.1 North America Antineoplastic Agents Market Size (2017-2028)

6.2 North America Antineoplastic Agents Market Size by Type

6.2.1 North America Antineoplastic Agents Market Size by Type (2017-2022)

6.2.2 North America Antineoplastic Agents Market Size by Type (2023-2028)

6.2.3 North America Antineoplastic Agents Market Share by Type (2017-2028)

6.3 North America Antineoplastic Agents Market Size by Application

6.3.1 North America Antineoplastic Agents Market Size by Application (2017-2022)

6.3.2 North America Antineoplastic Agents Market Size by Application (2023-2028)

6.3.3 North America Antineoplastic Agents Market Share by Application (2017-2028)

6.4 North America Antineoplastic Agents Market Size by Country

6.4.1 North America Antineoplastic Agents Market Size by Country (2017-2022)

6.4.2 North America Antineoplastic Agents Market Size by Country (2023-2028)

6.4.3 U.S.

6.4.4 Canada

7.1 Europe Antineoplastic Agents Market Size (2017-2028)

7.2 Europe Antineoplastic Agents Market Size by Type

7.2.1 Europe Antineoplastic Agents Market Size by Type (2017-2022)

7.2.2 Europe Antineoplastic Agents Market Size by Type (2023-2028)

7.2.3 Europe Antineoplastic Agents Market Share by Type (2017-2028)

7.3 Europe Antineoplastic Agents Market Size by Application

7.3.1 Europe Antineoplastic Agents Market Size by Application (2017-2022)

7.3.2 Europe Antineoplastic Agents Market Size by Application (2023-2028)

7.3.3 Europe Antineoplastic Agents Market Share by Application (2017-2028)

7.4 Europe Antineoplastic Agents Market Size by Country

7.4.1 Europe Antineoplastic Agents Market Size by Country (2017-2022)

7.4.2 Europe Antineoplastic Agents Market Size by Country (2023-2028)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8.1 Asia-Pacific Antineoplastic Agents Market Size (2017-2028)

8.2 Asia-Pacific Antineoplastic Agents Market Size by Type

8.2.1 Asia-Pacific Antineoplastic Agents Market Size by Type (2017-2022)

8.2.2 Asia-Pacific Antineoplastic Agents Market Size by Type (2023-2028)

8.2.3 Asia-Pacific Antineoplastic Agents Market Share by Type (2017-2028)

8.3 Asia-Pacific Antineoplastic Agents Market Size by Application

8.3.1 Asia-Pacific Antineoplastic Agents Market Size by Application (2017-2022)

8.3.2 Asia-Pacific Antineoplastic Agents Market Size by Application (2023-2028)

8.3.3 Asia-Pacific Antineoplastic Agents Market Share by Application (2017-2028)

8.4 Asia-Pacific Antineoplastic Agents Market Size by Region

8.4.1 Asia-Pacific Antineoplastic Agents Market Size by Region (2017-2022)

8.4.2 Asia-Pacific Antineoplastic Agents Market Size by Region (2023-2028)

8.4.3 China

8.4.4 Japan

8.4.5 South Korea

8.4.6 Southeast Asia

8.4.7 India

8.4.8 Australia

9.1 Latin America Antineoplastic Agents Market Size (2017-2028)

9.2 Latin America Antineoplastic Agents Market Size by Type

9.2.1 Latin America Antineoplastic Agents Market Size by Type (2017-2022)

9.2.2 Latin America Antineoplastic Agents Market Size by Type (2023-2028)

9.2.3 Latin America Antineoplastic Agents Market Share by Type (2017-2028)

9.3 Latin America Antineoplastic Agents Market Size by Application

9.3.1 Latin America Antineoplastic Agents Market Size by Application (2017-2022)

9.3.2 Latin America Antineoplastic Agents Market Size by Application (2023-2028)

9.3.3 Latin America Antineoplastic Agents Market Share by Application (2017-2028)

9.4 Latin America Antineoplastic Agents Market Size by Country

9.4.1 Latin America Antineoplastic Agents Market Size by Country (2017-2022)

9.4.2 Latin America Antineoplastic Agents Market Size by Country (2023-2028)

9.4.3 Mexico

9.4.4 Brazil

10.1 Middle East & Africa Antineoplastic Agents Market Size (2017-2028)

10.2 Middle East & Africa Antineoplastic Agents Market Size by Type

10.2.1 Middle East & Africa Antineoplastic Agents Market Size by Type (2017-2022)

10.2.2 Middle East & Africa Antineoplastic Agents Market Size by Type (2023-2028)

10.2.3 Middle East & Africa Antineoplastic Agents Market Share by Type (2017-2028)

10.3 Middle East & Africa Antineoplastic Agents Market Size by Application

10.3.1 Middle East & Africa Antineoplastic Agents Market Size by Application (2017-2022)

10.3.2 Middle East & Africa Antineoplastic Agents Market Size by Application (2023-2028)

10.3.3 Middle East & Africa Antineoplastic Agents Market Share by Application (2017-2028)

10.4 Middle East & Africa Antineoplastic Agents Market Size by Country

10.4.1 Middle East & Africa Antineoplastic Agents Market Size by Country (2017-2022)

10.4.2 Middle East & Africa Antineoplastic Agents Market Size by Country (2023-2028)

10.4.3 Turkey

10.4.4 Saudi Arabia

10.4.5 UAE

11.1 BMS

11.1.1 BMS Company Details

11.1.2 BMS Business Overview

11.1.3 BMS Antineoplastic Agents Introduction

11.1.4 BMS Revenue in Antineoplastic Agents Business (2017-2022)

11.1.5 BMS Recent Developments

11.2 MSD

11.2.1 MSD Company Details

11.2.2 MSD Business Overview

11.2.3 MSD Antineoplastic Agents Introduction

11.2.4 MSD Revenue in Antineoplastic Agents Business (2017-2022)

11.2.5 MSD Recent Developments

11.3 Johnson & Johnson

11.3.1 Johnson & Johnson Company Details

11.3.2 Johnson & Johnson Business Overview

11.3.3 Johnson & Johnson Antineoplastic Agents Introduction

11.3.4 Johnson & Johnson Revenue in Antineoplastic Agents Business (2017-2022)

11.3.5 Johnson & Johnson Recent Developments

11.4 Pfizer

11.4.1 Pfizer Company Details

11.4.2 Pfizer Business Overview

11.4.3 Pfizer Antineoplastic Agents Introduction

11.4.4 Pfizer Revenue in Antineoplastic Agents Business (2017-2022)

11.4.5 Pfizer Recent Developments

11.5 AstraZeneca

11.5.1 AstraZeneca Company Details

11.5.2 AstraZeneca Business Overview

11.5.3 AstraZeneca Antineoplastic Agents Introduction

11.5.4 AstraZeneca Revenue in Antineoplastic Agents Business (2017-2022)

11.5.5 AstraZeneca Recent Developments

11.6 Novartis

11.6.1 Novartis Company Details

11.6.2 Novartis Business Overview

11.6.3 Novartis Antineoplastic Agents Introduction

11.6.4 Novartis Revenue in Antineoplastic Agents Business (2017-2022)

11.6.5 Novartis Recent Developments

11.7 Sanofi

11.7.1 Sanofi Company Details

11.7.2 Sanofi Business Overview

11.7.3 Sanofi Antineoplastic Agents Introduction

11.7.4 Sanofi Revenue in Antineoplastic Agents Business (2017-2022)

11.7.5 Sanofi Recent Developments

11.8 Celgene

11.8.1 Celgene Company Details

11.8.2 Celgene Business Overview

11.8.3 Celgene Antineoplastic Agents Introduction

11.8.4 Celgene Revenue in Antineoplastic Agents Business (2017-2022)

11.8.5 Celgene Recent Developments

11.9 Roche

11.9.1 Roche Company Details

11.9.2 Roche Business Overview

11.9.3 Roche Antineoplastic Agents Introduction

11.9.4 Roche Revenue in Antineoplastic Agents Business (2017-2022)

11.9.5 Roche Recent Developments

11.10 Lilly

11.10.1 Lilly Company Details

11.10.2 Lilly Business Overview

11.10.3 Lilly Antineoplastic Agents Introduction

11.10.4 Lilly Revenue in Antineoplastic Agents Business (2017-2022)

11.10.5 Lilly Recent Developments

11.11 Bayer

11.11.1 Bayer Company Details

11.11.2 Bayer Business Overview

11.11.3 Bayer Antineoplastic Agents Introduction

11.11.4 Bayer Revenue in Antineoplastic Agents Business (2017-2022)

11.11.5 Bayer Recent Developments

11.12 Abraxis

11.12.1 Abraxis Company Details

11.12.2 Abraxis Business Overview

11.12.3 Abraxis Antineoplastic Agents Introduction

11.12.4 Abraxis Revenue in Antineoplastic Agents Business (2017-2022)

11.12.5 Abraxis Recent Developments

11.13 Gilead

11.13.1 Gilead Company Details

11.13.2 Gilead Business Overview

11.13.3 Gilead Antineoplastic Agents Introduction

11.13.4 Gilead Revenue in Antineoplastic Agents Business (2017-2022)

11.13.5 Gilead Recent Developments

11.14 Wto-Day Order Pharmaceutical

11.14.1 Wto-Day Order Pharmaceutical Company Details

11.14.2 Wto-Day Order Pharmaceutical Business Overview

11.14.3 Wto-Day Order Pharmaceutical Antineoplastic Agents Introduction

11.14.4 Wto-Day Order Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022)

11.14.5 Wto-Day Order Pharmaceutical Recent Developments

11.15 Sinopharm

11.15.1 Sinopharm Company Details

11.15.2 Sinopharm Business Overview

11.15.3 Sinopharm Antineoplastic Agents Introduction

11.15.4 Sinopharm Revenue in Antineoplastic Agents Business (2017-2022)

11.15.5 Sinopharm Recent Developments

11.16 Shandong Lvye Pharmaceutical

11.16.1 Shandong Lvye Pharmaceutical Company Details

11.16.2 Shandong Lvye Pharmaceutical Business Overview

11.16.3 Shandong Lvye Pharmaceutical Antineoplastic Agents Introduction

11.16.4 Shandong Lvye Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022)

11.16.5 Shandong Lvye Pharmaceutical Recent Developments

11.17 CTTQ

11.17.1 CTTQ Company Details

11.17.2 CTTQ Business Overview

11.17.3 CTTQ Antineoplastic Agents Introduction

11.17.4 CTTQ Revenue in Antineoplastic Agents Business (2017-2022)

11.17.5 CTTQ Recent Developments

11.18 Jiangsu Hengrui Pharmaceutical

11.18.1 Jiangsu Hengrui Pharmaceutical Company Details

11.18.2 Jiangsu Hengrui Pharmaceutical Business Overview

11.18.3 Jiangsu Hengrui Pharmaceutical Antineoplastic Agents Introduction

11.18.4 Jiangsu Hengrui Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022)

11.18.5 Jiangsu Hengrui Pharmaceutical Recent Developments

11.19 Qilu Pharmaceutical

11.19.1 Qilu Pharmaceutical Company Details

11.19.2 Qilu Pharmaceutical Business Overview

11.19.3 Qilu Pharmaceutical Antineoplastic Agents Introduction

11.19.4 Qilu Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022)

11.19.5 Qilu Pharmaceutical Recent Developments

11.20 Baekdu Mountain Pharmaceutical

11.20.1 Baekdu Mountain Pharmaceutical Company Details

11.20.2 Baekdu Mountain Pharmaceutical Business Overview

11.20.3 Baekdu Mountain Pharmaceutical Antineoplastic Agents Introduction

11.20.4 Baekdu Mountain Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022)

11.20.5 Baekdu Mountain Pharmaceutical Recent Developments

11.21 Baida Pharmaceutical

11.21.1 Baida Pharmaceutical Company Details

11.21.2 Baida Pharmaceutical Business Overview

11.21.3 Baida Pharmaceutical Antineoplastic Agents Introduction

11.21.4 Baida Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022)

11.21.5 Baida Pharmaceutical Recent Developments

11.22 Jiangsu Haosen Pharmaceutical Group

11.22.1 Jiangsu Haosen Pharmaceutical Group Company Details

11.22.2 Jiangsu Haosen Pharmaceutical Group Business Overview

11.22.3 Jiangsu Haosen Pharmaceutical Group Antineoplastic Agents Introduction

11.22.4 Jiangsu Haosen Pharmaceutical Group Revenue in Antineoplastic Agents Business (2017-2022)

11.22.5 Jiangsu Haosen Pharmaceutical Group Recent Developments

11.23 Hainan Chang'an International Pharmaceutical

11.23.1 Hainan Chang'an International Pharmaceutical Company Details

11.23.2 Hainan Chang'an International Pharmaceutical Business Overview

11.23.3 Hainan Chang'an International Pharmaceutical Antineoplastic Agents Introduction

11.23.4 Hainan Chang'an International Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022)

11.23.5 Hainan Chang'an International Pharmaceutical Recent Developments

11.24 Zhejiang Kanglaite Pharmaceutical

11.24.1 Zhejiang Kanglaite Pharmaceutical Company Details

11.24.2 Zhejiang Kanglaite Pharmaceutical Business Overview

11.24.3 Zhejiang Kanglaite Pharmaceutical Antineoplastic Agents Introduction

11.24.4 Zhejiang Kanglaite Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022)

11.24.5 Zhejiang Kanglaite Pharmaceutical Recent Developments

11.25 Shandong New Era Pharmaceutical

11.25.1 Shandong New Era Pharmaceutical Company Details

11.25.2 Shandong New Era Pharmaceutical Business Overview

11.25.3 Shandong New Era Pharmaceutical Antineoplastic Agents Introduction

11.25.4 Shandong New Era Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022)

11.25.5 Shandong New Era Pharmaceutical Recent Developments

11.26 Liaoning Novino Pharmaceutical

11.26.1 Liaoning Novino Pharmaceutical Company Details

11.26.2 Liaoning Novino Pharmaceutical Business Overview

11.26.3 Liaoning Novino Pharmaceutical Antineoplastic Agents Introduction

11.26.4 Liaoning Novino Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022)

11.26.5 Liaoning Novino Pharmaceutical Recent Developments

11.27 Maanshan Fengyuan Pharmaceutical

11.27.1 Maanshan Fengyuan Pharmaceutical Company Details

11.27.2 Maanshan Fengyuan Pharmaceutical Business Overview

11.27.3 Maanshan Fengyuan Pharmaceutical Antineoplastic Agents Introduction

11.27.4 Maanshan Fengyuan Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022)

11.27.5 Maanshan Fengyuan Pharmaceutical Recent Developments

11.28 Meiluo Pharmaceutical

11.28.1 Meiluo Pharmaceutical Company Details

11.28.2 Meiluo Pharmaceutical Business Overview

11.28.3 Meiluo Pharmaceutical Antineoplastic Agents Introduction

11.28.4 Meiluo Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022)

11.28.5 Meiluo Pharmaceutical Recent Developments

11.29 Shandong Luoxin Pharmaceutical Group

11.29.1 Shandong Luoxin Pharmaceutical Group Company Details

11.29.2 Shandong Luoxin Pharmaceutical Group Business Overview

11.29.3 Shandong Luoxin Pharmaceutical Group Antineoplastic Agents Introduction

11.29.4 Shandong Luoxin Pharmaceutical Group Revenue in Antineoplastic Agents Business (2017-2022)

11.29.5 Shandong Luoxin Pharmaceutical Group Recent Developments

11.30 Zhejiang Yatai Pharmaceutical

11.30.1 Zhejiang Yatai Pharmaceutical Company Details

11.30.2 Zhejiang Yatai Pharmaceutical Business Overview

11.30.3 Zhejiang Yatai Pharmaceutical Antineoplastic Agents Introduction

11.30.4 Zhejiang Yatai Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022)

11.30.5 Zhejiang Yatai Pharmaceutical Recent Developments

11.31 Tesaro (GSK)

11.31.1 Tesaro (GSK) Company Details

11.31.2 Tesaro (GSK) Business Overview

11.31.3 Tesaro (GSK) Antineoplastic Agents Introduction

11.31.4 Tesaro (GSK) Revenue in Antineoplastic Agents Business (2017-2022)

11.31.5 Tesaro (GSK) Recent Developments

11.32 Eisai

11.32.1 Eisai Company Details

11.32.2 Eisai Business Overview

11.32.3 Eisai Antineoplastic Agents Introduction

11.32.4 Eisai Revenue in Antineoplastic Agents Business (2017-2022)

11.32.5 Eisai Recent Developments

11.33 Biogen Idec

11.33.1 Biogen Idec Company Details

11.33.2 Biogen Idec Business Overview

11.33.3 Biogen Idec Antineoplastic Agents Introduction

11.33.4 Biogen Idec Revenue in Antineoplastic Agents Business (2017-2022)

11.33.5 Biogen Idec Recent Developments

11.34 Teva

11.34.1 Teva Company Details

11.34.2 Teva Business Overview

11.34.3 Teva Antineoplastic Agents Introduction

11.34.4 Teva Revenue in Antineoplastic Agents Business (2017-2022)

11.34.5 Teva Recent Developments

11.35 AbbVie

11.35.1 AbbVie Company Details

11.35.2 AbbVie Business Overview

11.35.3 AbbVie Antineoplastic Agents Introduction

11.35.4 AbbVie Revenue in Antineoplastic Agents Business (2017-2022)

11.35.5 AbbVie Recent Developments

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Author Details

13.3 Disclaimer

List of Tables

    Table 1. Global Antineoplastic Agents Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028

    Table 2. Key Players of Chemotherapy

    Table 3. Key Players of Targeted Therapy

    Table 4. Key Players of Immunotherapy

    Table 5. Key Players of Hormonal Therapy (Biologic Therapy)

    Table 6. Key Players of Others

    Table 7. Global Antineoplastic Agents Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028

    Table 8. Global Antineoplastic Agents Market Size by Region (US$ Million): 2017 VS 2021 VS 2028

    Table 9. Global Antineoplastic Agents Market Size by Region (2017-2022) & (US$ Million)

    Table 10. Global Antineoplastic Agents Market Share by Region (2017-2022)

    Table 11. Global Antineoplastic Agents Forecasted Market Size by Region (2023-2028) & (US$ Million)

    Table 12. Global Antineoplastic Agents Market Share by Region (2023-2028)

    Table 13. Antineoplastic Agents Market Trends

    Table 14. Antineoplastic Agents Market Drivers

    Table 15. Antineoplastic Agents Market Challenges

    Table 16. Antineoplastic Agents Market Restraints

    Table 17. Global Antineoplastic Agents Revenue by Players (2017-2022) & (US$ Million)

    Table 18. Global Antineoplastic Agents Revenue Share by Players (2017-2022)

    Table 19. Global Top Antineoplastic Agents by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antineoplastic Agents as of 2021)

    Table 20. Ranking of Global Top Antineoplastic Agents Companies by Revenue (US$ Million) in 2021

    Table 21. Global 5 Largest Players Market Share by Antineoplastic Agents Revenue (CR5 and HHI) & (2017-2022)

    Table 22. Key Players Headquarters and Area Served

    Table 23. Key Players Antineoplastic Agents Product Solution and Service

    Table 24. Date of Enter into Antineoplastic Agents Market

    Table 25. Mergers & Acquisitions, Expansion Plans

    Table 26. Global Antineoplastic Agents Market Size by Type (2017-2022) & (US$ Million)

    Table 27. Global Antineoplastic Agents Revenue Market Share by Type (2017-2022)

    Table 28. Global Antineoplastic Agents Forecasted Market Size by Type (2023-2028) & (US$ Million)

    Table 29. Global Antineoplastic Agents Revenue Market Share by Type (2023-2028)

    Table 30. Global Antineoplastic Agents Market Size by Application (2017-2022) & (US$ Million)

    Table 31. Global Antineoplastic Agents Revenue Share by Application (2017-2022)

    Table 32. Global Antineoplastic Agents Forecasted Market Size by Application (2023-2028) & (US$ Million)

    Table 33. Global Antineoplastic Agents Revenue Share by Application (2023-2028)

    Table 34. North America Antineoplastic Agents Market Size by Type (2017-2022) & (US$ Million)

    Table 35. North America Antineoplastic Agents Market Size by Type (2023-2028) & (US$ Million)

    Table 36. North America Antineoplastic Agents Market Size by Application (2017-2022) & (US$ Million)

    Table 37. North America Antineoplastic Agents Market Size by Application (2023-2028) & (US$ Million)

    Table 38. North America Antineoplastic Agents Market Size by Country (2017-2022) & (US$ Million)

    Table 39. North America Antineoplastic Agents Market Size by Country (2023-2028) & (US$ Million)

    Table 40. Europe Antineoplastic Agents Market Size by Type (2017-2022) & (US$ Million)

    Table 41. Europe Antineoplastic Agents Market Size by Type (2023-2028) & (US$ Million)

    Table 42. Europe Antineoplastic Agents Market Size by Application (2017-2022) & (US$ Million)

    Table 43. Europe Antineoplastic Agents Market Size by Application (2023-2028) & (US$ Million)

    Table 44. Europe Antineoplastic Agents Market Size by Country (2017-2022) & (US$ Million)

    Table 45. Europe Antineoplastic Agents Market Size by Country (2023-2028) & (US$ Million)

    Table 46. Asia Pacific Antineoplastic Agents Market Size by Type (2017-2022) & (US$ Million)

    Table 47. Asia Pacific Antineoplastic Agents Market Size by Type (2023-2028) & (US$ Million)

    Table 48. Asia Pacific Antineoplastic Agents Market Size by Application (2017-2022) & (US$ Million)

    Table 49. Asia Pacific Antineoplastic Agents Market Size by Application (2023-2028) & (US$ Million)

    Table 50. Asia Pacific Antineoplastic Agents Market Size by Region (2017-2022) & (US$ Million)

    Table 51. Asia Pacific Antineoplastic Agents Market Size by Region (2023-2028) & (US$ Million)

    Table 52. Latin America Antineoplastic Agents Market Size by Type (2017-2022) & (US$ Million)

    Table 53. Latin America Antineoplastic Agents Market Size by Type (2023-2028) & (US$ Million)

    Table 54. Latin America Antineoplastic Agents Market Size by Application (2017-2022) & (US$ Million)

    Table 55. Latin America Antineoplastic Agents Market Size by Application (2023-2028) & (US$ Million)

    Table 56. Latin America Antineoplastic Agents Market Size by Country (2017-2022) & (US$ Million)

    Table 57. Latin America Antineoplastic Agents Market Size by Country (2023-2028) & (US$ Million)

    Table 58. Middle East and Africa Antineoplastic Agents Market Size by Type (2017-2022) & (US$ Million)

    Table 59. Middle East and Africa Antineoplastic Agents Market Size by Type (2023-2028) & (US$ Million)

    Table 60. Middle East and Africa Antineoplastic Agents Market Size by Application (2017-2022) & (US$ Million)

    Table 61. Middle East and Africa Antineoplastic Agents Market Size by Application (2023-2028) & (US$ Million)

    Table 62. Middle East and Africa Antineoplastic Agents Market Size by Country (2017-2022) & (US$ Million)

    Table 63. Middle East and Africa Antineoplastic Agents Market Size by Country (2023-2028) & (US$ Million)

    Table 64. BMS Company Details

    Table 65. BMS Business Overview

    Table 66. BMS Antineoplastic Agents Product

    Table 67. BMS Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 68. BMS Recent Developments

    Table 69. MSD Company Details

    Table 70. MSD Business Overview

    Table 71. MSD Antineoplastic Agents Product

    Table 72. MSD Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 73. MSD Recent Developments

    Table 74. Johnson & Johnson Company Details

    Table 75. Johnson & Johnson Business Overview

    Table 76. Johnson & Johnson Antineoplastic Agents Product

    Table 77. Johnson & Johnson Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 78. Johnson & Johnson Recent Developments

    Table 79. Pfizer Company Details

    Table 80. Pfizer Business Overview

    Table 81. Pfizer Antineoplastic Agents Product

    Table 82. Pfizer Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 83. Pfizer Recent Developments

    Table 84. AstraZeneca Company Details

    Table 85. AstraZeneca Business Overview

    Table 86. AstraZeneca Antineoplastic Agents Product

    Table 87. AstraZeneca Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 88. AstraZeneca Recent Developments

    Table 89. Novartis Company Details

    Table 90. Novartis Business Overview

    Table 91. Novartis Antineoplastic Agents Product

    Table 92. Novartis Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 93. Novartis Recent Developments

    Table 94. Sanofi Company Details

    Table 95. Sanofi Business Overview

    Table 96. Sanofi Antineoplastic Agents Product

    Table 97. Sanofi Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 98. Sanofi Recent Developments

    Table 99. Celgene Company Details

    Table 100. Celgene Business Overview

    Table 101. Celgene Antineoplastic Agents Product

    Table 102. Celgene Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 103. Celgene Recent Developments

    Table 104. Roche Company Details

    Table 105. Roche Business Overview

    Table 106. Roche Antineoplastic Agents Product

    Table 107. Roche Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 108. Roche Recent Developments

    Table 109. Lilly Company Details

    Table 110. Lilly Business Overview

    Table 111. Lilly Antineoplastic Agents Product

    Table 112. Lilly Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 113. Lilly Recent Developments

    Table 114. Bayer Company Details

    Table 115. Bayer Business Overview

    Table 116. Bayer Antineoplastic Agents Product

    Table 117. Bayer Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 118. Bayer Recent Developments

    Table 119. Abraxis Company Details

    Table 120. Abraxis Business Overview

    Table 121. Abraxis Antineoplastic Agents Product

    Table 122. Abraxis Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 123. Abraxis Recent Developments

    Table 124. Gilead Company Details

    Table 125. Gilead Business Overview

    Table 126. Gilead Antineoplastic Agents Product

    Table 127. Gilead Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 128. Gilead Recent Developments

    Table 129. Wto-Day Order Pharmaceutical Company Details

    Table 130. Wto-Day Order Pharmaceutical Business Overview

    Table 131. Wto-Day Order Pharmaceutical Antineoplastic Agents Product

    Table 132. Wto-Day Order Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 133. Wto-Day Order Pharmaceutical Recent Developments

    Table 134. Sinopharm Company Details

    Table 135. Sinopharm Business Overview

    Table 136. Sinopharm Antineoplastic Agents Product

    Table 137. Sinopharm Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 138. Sinopharm Recent Developments

    Table 139. Shandong Lvye Pharmaceutical Company Details

    Table 140. Shandong Lvye Pharmaceutical Business Overview

    Table 141. Shandong Lvye Pharmaceutical Antineoplastic Agents Product

    Table 142. Shandong Lvye Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 143. Shandong Lvye Pharmaceutical Recent Developments

    Table 144. CTTQ Company Details

    Table 145. CTTQ Business Overview

    Table 146. CTTQ Antineoplastic Agents Product

    Table 147. CTTQ Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 148. CTTQ Recent Developments

    Table 149. Jiangsu Hengrui Pharmaceutical Company Details

    Table 150. Jiangsu Hengrui Pharmaceutical Business Overview

    Table 151. Jiangsu Hengrui Pharmaceutical Antineoplastic Agents Product

    Table 152. Jiangsu Hengrui Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 153. Jiangsu Hengrui Pharmaceutical Recent Developments

    Table 154. Qilu Pharmaceutical Company Details

    Table 155. Qilu Pharmaceutical Business Overview

    Table 156. Qilu Pharmaceutical Antineoplastic Agents Product

    Table 157. Qilu Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 158. Qilu Pharmaceutical Recent Developments

    Table 159. Baekdu Mountain Pharmaceutical Company Details

    Table 160. Baekdu Mountain Pharmaceutical Business Overview

    Table 161. Baekdu Mountain Pharmaceutical Antineoplastic Agents Product

    Table 162. Baekdu Mountain Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 163. Baekdu Mountain Pharmaceutical Recent Developments

    Table 164. Baida Pharmaceutical Company Details

    Table 165. Baida Pharmaceutical Business Overview

    Table 166. Baida Pharmaceutical Antineoplastic Agents Product

    Table 167. Baida Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 168. Baida Pharmaceutical Recent Developments

    Table 169. Jiangsu Haosen Pharmaceutical Group Company Details

    Table 170. Jiangsu Haosen Pharmaceutical Group Business Overview

    Table 171. Jiangsu Haosen Pharmaceutical Group Antineoplastic Agents Product

    Table 172. Jiangsu Haosen Pharmaceutical Group Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 173. Jiangsu Haosen Pharmaceutical Group Recent Developments

    Table 174. Hainan Chang'an International Pharmaceutical Company Details

    Table 175. Hainan Chang'an International Pharmaceutical Business Overview

    Table 176. Hainan Chang'an International Pharmaceutical Antineoplastic Agents Product

    Table 177. Hainan Chang'an International Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 178. Hainan Chang'an International Pharmaceutical Recent Developments

    Table 179. Zhejiang Kanglaite Pharmaceutical Company Details

    Table 180. Zhejiang Kanglaite Pharmaceutical Business Overview

    Table 181. Zhejiang Kanglaite Pharmaceutical Antineoplastic Agents Product

    Table 182. Zhejiang Kanglaite Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 183. Zhejiang Kanglaite Pharmaceutical Recent Developments

    Table 184. Shandong New Era Pharmaceutical Company Details

    Table 185. Shandong New Era Pharmaceutical Business Overview

    Table 186. Shandong New Era Pharmaceutical Antineoplastic Agents Product

    Table 187. Shandong New Era Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 188. Shandong New Era Pharmaceutical Recent Developments

    Table 189. Liaoning Novino Pharmaceutical Company Details

    Table 190. Liaoning Novino Pharmaceutical Business Overview

    Table 191. Liaoning Novino Pharmaceutical Antineoplastic Agents Product

    Table 192. Liaoning Novino Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 193. Liaoning Novino Pharmaceutical Recent Developments

    Table 194. Maanshan Fengyuan Pharmaceutical Company Details

    Table 195. Maanshan Fengyuan Pharmaceutical Business Overview

    Table 196. Maanshan Fengyuan Pharmaceutical Antineoplastic Agents Product

    Table 197. Maanshan Fengyuan Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 198. Maanshan Fengyuan Pharmaceutical Recent Developments

    Table 199. Meiluo Pharmaceutical Company Details

    Table 200. Meiluo Pharmaceutical Business Overview

    Table 201. Meiluo Pharmaceutical Antineoplastic Agents Product

    Table 202. Meiluo Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 203. Meiluo Pharmaceutical Recent Developments

    Table 204. Shandong Luoxin Pharmaceutical Group Company Details

    Table 205. Shandong Luoxin Pharmaceutical Group Business Overview

    Table 206. Shandong Luoxin Pharmaceutical Group Antineoplastic Agents Product

    Table 207. Shandong Luoxin Pharmaceutical Group Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 208. Shandong Luoxin Pharmaceutical Group Recent Developments

    Table 209. Zhejiang Yatai Pharmaceutical Company Details

    Table 210. Zhejiang Yatai Pharmaceutical Business Overview

    Table 211. Zhejiang Yatai Pharmaceutical Antineoplastic Agents Product

    Table 212. Zhejiang Yatai Pharmaceutical Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 213. Zhejiang Yatai Pharmaceutical Recent Developments

    Table 214. Tesaro (GSK) Company Details

    Table 215. Tesaro (GSK) Business Overview

    Table 216. Tesaro (GSK) Antineoplastic Agents Product

    Table 217. Tesaro (GSK) Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 218. Tesaro (GSK) Recent Developments

    Table 219. Eisai Company Details

    Table 220. Eisai Business Overview

    Table 221. Eisai Antineoplastic Agents Product

    Table 222. Eisai Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 223. Eisai Recent Developments

    Table 224. Biogen Idec Company Details

    Table 225. Biogen Idec Business Overview

    Table 226. Biogen Idec Antineoplastic Agents Product

    Table 227. Biogen Idec Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 228. Biogen Idec Recent Developments

    Table 229. Teva Company Details

    Table 230. Teva Business Overview

    Table 231. Teva Antineoplastic Agents Product

    Table 232. Teva Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 233. Teva Recent Developments

    Table 234. AbbVie Company Details

    Table 235. AbbVie Business Overview

    Table 236. AbbVie Antineoplastic Agents Product

    Table 237. AbbVie Revenue in Antineoplastic Agents Business (2017-2022) & (US$ Million)

    Table 238. AbbVie Recent Developments

    Table 239. Research Programs/Design for This Report

    Table 240. Key Data Information from Secondary Sources

    Table 241. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Antineoplastic Agents Market Share by Type: 2021 VS 2028

    Figure 2. Chemotherapy Features

    Figure 3. Targeted Therapy Features

    Figure 4. Immunotherapy Features

    Figure 5. Hormonal Therapy (Biologic Therapy) Features

    Figure 6. Others Features

    Figure 7. Global Antineoplastic Agents Market Share by Application: 2021 VS 2028

    Figure 8. Plant Medicine Case Studies

    Figure 9. Hormone Case Studies

    Figure 10. Platinum Compounds Case Studies

    Figure 11. Metabolism Of Drug Resistance Case Studies

    Figure 12. Targeting Small Molecules Case Studies

    Figure 13. Drugs For Cancer Case Studies

    Figure 14. Antibiotic Case Studies

    Figure 15. Alkylating Agent Case Studies

    Figure 16. Chemoradiotherapy Protectant Case Studies

    Figure 17. Other Case Studies

    Figure 18. Antineoplastic Agents Report Years Considered

    Figure 19. Global Antineoplastic Agents Market Size (US$ Million), Year-over-Year: 2017-2028

    Figure 20. Global Antineoplastic Agents Market Size, (US$ Million), 2017 VS 2021 VS 2028

    Figure 21. Global Antineoplastic Agents Market Share by Region: 2021 VS 2028

    Figure 22. Global Antineoplastic Agents Market Share by Players in 2021

    Figure 23. Global Top Antineoplastic Agents Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antineoplastic Agents as of 2021)

    Figure 24. The Top 10 and 5 Players Market Share by Antineoplastic Agents Revenue in 2021

    Figure 25. North America Antineoplastic Agents Market Size YoY (2017-2028) & (US$ Million)

    Figure 26. North America Antineoplastic Agents Market Size Market Share by Type (2017-2028)

    Figure 27. North America Antineoplastic Agents Market Size Market Share by Application (2017-2028)

    Figure 28. North America Antineoplastic Agents Market Size Share by Country (2017-2028)

    Figure 29. United States Antineoplastic Agents Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 30. Canada Antineoplastic Agents Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 31. Europe Antineoplastic Agents Market Size YoY (2017-2028) & (US$ Million)

    Figure 32. Europe Antineoplastic Agents Market Size Market Share by Type (2017-2028)

    Figure 33. Europe Antineoplastic Agents Market Size Market Share by Application (2017-2028)

    Figure 34. Europe Antineoplastic Agents Market Size Share by Country (2017-2028)

    Figure 35. Germany Antineoplastic Agents Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 36. France Antineoplastic Agents Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 37. U.K. Antineoplastic Agents Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 38. Italy Antineoplastic Agents Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 39. Russia Antineoplastic Agents Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 40. Nordic Countries Antineoplastic Agents Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 41. Asia-Pacific Antineoplastic Agents Market Size YoY (2017-2028) & (US$ Million)

    Figure 42. Asia Pacific Antineoplastic Agents Market Size Market Share by Type (2017-2028)

    Figure 43. Asia Pacific Antineoplastic Agents Market Size Market Share by Application (2017-2028)

    Figure 44. Asia Pacific Antineoplastic Agents Market Size Share by Region (2017-2028)

    Figure 45. China Antineoplastic Agents Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 46. Japan Antineoplastic Agents Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 47. South Korea Antineoplastic Agents Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 48. Southeast Asia Antineoplastic Agents Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 49. India Antineoplastic Agents Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 50. Australia Antineoplastic Agents Market Size YoY Growth (2017-2028) & (US$ Million)

List of Figures

    Figure 51. Latin America Antineoplastic Agents Market Size YoY (2017-2028) & (US$ Million)

    Figure 52. Latin America Antineoplastic Agents Market Size Market Share by Type (2017-2028)

    Figure 53. Latin America Antineoplastic Agents Market Size Market Share by Application (2017-2028)

    Figure 54. Latin America Antineoplastic Agents Market Size Share by Country (2017-2028)

    Figure 55. Mexico Antineoplastic Agents Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 56. Brazil Antineoplastic Agents Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 57. Middle East & Africa Antineoplastic Agents Market Size YoY (2017-2028) & (US$ Million)

    Figure 58. Middle East and Africa Antineoplastic Agents Market Size Market Share by Type (2017-2028)

    Figure 59. Middle East and Africa Antineoplastic Agents Market Size Market Share by Application (2017-2028)

    Figure 60. Middle East and Africa Antineoplastic Agents Market Size Share by Country (2017-2028)

    Figure 61. Turkey Antineoplastic Agents Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 62. Saudi Arabia Antineoplastic Agents Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 63. UAE Antineoplastic Agents Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 64. BMS Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 65. MSD Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 66. Johnson & Johnson Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 67. Pfizer Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 68. AstraZeneca Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 69. Novartis Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 70. Sanofi Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 71. Celgene Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 72. Roche Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 73. Lilly Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 74. Bayer Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 75. Abraxis Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 76. Gilead Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 77. Wto-Day Order Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 78. Sinopharm Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 79. Shandong Lvye Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 80. CTTQ Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 81. Jiangsu Hengrui Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 82. Qilu Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 83. Baekdu Mountain Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 84. Baida Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 85. Jiangsu Haosen Pharmaceutical Group Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 86. Hainan Chang'an International Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 87. Zhejiang Kanglaite Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 88. Shandong New Era Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 89. Liaoning Novino Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 90. Maanshan Fengyuan Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 91. Meiluo Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 92. Shandong Luoxin Pharmaceutical Group Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 93. Zhejiang Yatai Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 94. Tesaro (GSK) Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 95. Eisai Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 96. Biogen Idec Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 97. Teva Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 98. AbbVie Revenue Growth Rate in Antineoplastic Agents Business (2017-2022)

    Figure 99. Bottom-up and Top-down Approaches for This Report

    Figure 100. Data Triangulation

    Figure 101. Key Executives Interviewed